Background/Objectives: Low serum 25-hydroxyvitamin D (25(OH)D) concentrations are related to increased mortality. One possible explanation could be an association between serum 25(OH)D and serum lipids. Subjects/Methods: The study was performed at the University of Tromsø, Northern Norway. In total, 8018 nonsmoking and 2087 smoking subjects were included in a cross-sectional study performed in 2008, and 1762 nonsmoking and 397 smoking subjects in a longitudinal study from 1994/1995 to 2008. Nonfasting serum 25(OH)D, total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), LDL-C/HDL-C ratio and triacylglycerol (TAG) were measured. Results: After adjustment for gender, age, sample month and body mass index in the cross-sectional study, there was a significant increase in serum TC, HDL-C and LDL-C, and a significant decrease in serum LDL-C/HDL-C ratio and TAG across increasing serum 25(OH)D quartiles. For serum HDL-C and TAG in nonsmokers the differences between the means for the highest and lowest serum 25(OH)D quartiles were 6.0 and 18.5%, respectively. In the longitudinal study, an increase in serum 25(OH)D was associated with a significant decrease in serum TAG. Conclusions: There is a cross-sectional association between serum 25(OH)D and serum lipids, and a longitudinal association over 14 years between serum 25(OH)D and TAG, which may contribute to explain the relation between low serum 25(OH)D concentrations and mortality.
Introduction
The serum concentration of 25-hydroxyvitamin D (25(OH)D) is generally accepted for evaluating vitamin D status and has been shown to relate inversely to the risks of all-cause and cardiovascular mortality (Dobnig et al., 2008; Melamed et al., 2008; Pilz et al., 2009) . Whether this reflects a causal relationship or just that subjects with good health spend more time outdoors in the sun and therefore produce more vitamin D in the skin, and/or eat more fatty fish and use more vitamin D supplements (DeLuca, 2004) , is not known. However, the relationship was recently substantiated in a meta-analysis of 18 randomized controlled trials including more than 57 000 subjects, which strongly suggests that these associations are causal (Autier and Gandini, 2007) . In that meta-analysis the relative risk for mortality was 0.93 for those supplemented with vitamin D as compared to the controls, but the difference was of borderline statistical significance with a confidence interval of 0.87-0.99.
It appears that the increased mortality in subjects with low serum 25(OH)D concentrations is particularly related to cardiovascular diseases (Dobnig et al., 2008; Pilz et al., 2009) , which could be explained by the well-documented associations between low serum 25(OH)D concentrations and increased blood pressure (Scragg et al., 2007; Witham et al., 2009) , blood glucose (Need et al., 2005) and body mass index (BMI) (Snijder et al., 2005) . However, the relation between serum 25(OH)D and serum lipids, which are among the major risk factors for cardiovascular disease (Kannel et al., 1971) , is more uncertain (Ford et al., 2005; John et al., 2005; Martins et al., 2007; Forouhi et al., 2008; Hyppönen et al., 2008; Gannagé-Yared et al., 2009; Lee et al., 2009) . We have therefore examined the cross-sectional relation between serum 25(OH)D and serum lipids in 12 000 subjects from the Tromsø study, and also examined the longitudinal relation between change in serum 25(OH)D concentrations and change in serum lipids over a 14 years period.
Participants and methods

Participants
The Tromsø study, conducted by the University of Tromsø in cooperation with the National Health Screening Service, is a longitudinal population-based multipurpose study focusing on lifestyle-related diseases (Thelle et al., 1976) . The fourth survey in 1994-1995 (1994 in the following for simplicity) was performed in two phases, and all residents in the Tromsø municipality aged 25 years or older were invited to participate in the first phase of the study. A total of 27 158 persons participated, providing an attendance rate of 77% among eligible inhabitants. All men aged 55-74 years, all women aged 50-74 years, and a 5-10% sample of the remaining age groups between 25 and 84 years were preselected to a second phase of the survey, and 7965 persons, or 78% of those invited, attended (Jorde and Bonaa, 2000) . The sixth survey was performed in 2008 and the following groups were invited: those who participated in the second phase of the fourth survey, a random 10% sample of subjects 30-39 years old, all subjects 40-42 years old, a 40% random sample of subjects 43-59 years old and all subjects 60-87 years old. In total, 19 762 subjects were invited and 12 984 subjects (65.7%) attended. Subjects with diabetes and subjects using lipid-lowering drugs were analyzed separately.
Measurements
In both surveys the participants filled in questionnaires covering medical history, lipid-lowering medication and lifestyle factors including smoking. Blood samples were drawn in a nonfasting state. Serum lipids were analyzed consecutively both in the fourth survey in 1994 and in the sixth survey in 2008. In the fourth survey serum total cholesterol (TC) and triacylglycerol (TAG) levels were analyzed by enzymatic colorimetric methods with commercial kits (CHOD-PAP for TC and GPO-PAP for TAG; Boehringer-Mannheim, Mannheim, Germany). Serum highdensity lipoprotein cholesterol (HDL-C) was measured after the precipitation of lower-density lipoproteins with heparin and manganese chloride. The serum low-density lipoprotein cholesterol (LDL-C) was calculated using the formula LDL-C ¼ TCÀHDL-CÀ(TAG Â 0.46), provided the serum TAG value was o4.0 mmol/l. In the sixth survey serum TC, TAG and HDL-C were analyzed with enzymatic colorimetric assays (CHOD-PAP, GPO-PAP, HDL-C plus 3rd generation, LDL-C plus 2nd generation, respectively, from Roche Diagnostics, Mannheim, Germany) using an automated clinical chemistry analyzer (Modular P; Roche Diagnostics). The current reference intervals were those established in collaboration with the Nordic Reference Interval Project, and were as follows for TC: 18-29 years, 2.9-6.1 mmol/l; 30-49 years, 3.3-6.9 mmol/l and X50 years, 3.9-7.8 mmol/l; for TAG: 0.5-2.6 mmol/l; for HDL-cholesterol: women, 1.0-2.7 mmol/l and men, 0.8-2.1 mmol/l; and for LDLcholesterol: 18-29 years, 1.2-4.3 mmol/l; 30-49 years, 1.4-4.7 mmol/l and X50 years, 2.0-5.3 mmol/l.
Sera from the second phase of the fourth Tromsø study were stored at À70 1C, and after a median storage time of 13 years, thawed in March 2008 and analyzed for 25(OH)D whereas sera from the sixth Tromsø study were analyzed for 25(OH)D consecutively by immunometry (electrochemiluminescence immunoassay), using an automated clinical chemistry analyzer (Modular E170; Roche Diagnostics; Leino et al., 2008; Roth et al., 2008; Wagner et al., 2009) . According to the manufacturers, the assay has, for total analytical precision, a coefficient of variation p7.8% as judged in any of three concentrations (48.6-73.8-177 .0 nmol/l). The crossreactivity with 25(OH)D 2 was o10% and the analytical sensitivity was 10 nmol/l. At present, the laboratory has no reference values for 25(OH)D, but the manufacturer provides a population-based reference range of 27.7-107.0 nmol/l for adults as a guideline. This analysis has been approved by the Norwegian Accreditation Authority. With this method we have found smokers to have 15-20% higher serum 25(OH)D concentrations than nonsmokers, which we have not found when measuring serum 25(OH)D with other immunological, high pressure liquid chromatography or liquid chromatography-tandem mass spectrometry methods (Grimnes et al., 2010) . For this discrepancy we have at present no explanation, and have therefore decided to present nonsmokers and smokers separately.
Statistics
Normal distribution was evaluated with visual inspection of histograms and determination of skewness and kurtosis, and except for serum TAG all variables used as dependent variables were considered normally distributed. After log transformation serum TAG attained normal distribution and was used as such in the statistical analyses. Linear trends across serum 25(OH)D quartiles were tested with linear regression with use of covariates as described in the tables. In the cross-sectional analyses month of blood sampling was adjusted for using dummy variables. 
Results
Cross-sectional study 2008
A total of 12 984 subjects attended the study and 12 817 had valid serum 25(OH)D measurements. Among these, 622 subjects had diabetes, and a further 2090 subjects were using lipid-lowering drugs. Among the remaining 10 105 subjects, 8018 were nonsmokers and 2087 were current smokers. The baseline characteristics of these subjects are shown in Table 1 .
After adjusting for confounders, there was (in the 8018 nonsmokers) a significant increase in age, a decrease in BMI, an increase in TC, HDL-C and LDL-C, and a decrease in LDL-C/HDL-C ratio and TAG across increasing serum 25(OH)D quartiles (Table 2) as well as when the cohort was stratified according to serum 25(OH)D concentrations of 25, 50 and 75 nmol/l (Table 3) . These significant trends were found in both men and women (data not shown). After adjustment for confounders the difference between the lowest and the highest serum 25(OH)D quartiles was most pronounced for HDL-C and TAG, being for nonsmokers 6.0 and 18.5%, respectively (Table 2) .
Except for serum HDL-C and LDL-C, similar results were observed for the 2087 smokers (Table 4) . In nonsmoking subjects with diabetes but not using lipid-lowering drugs (n ¼ 239) and in nonsmoking subjects without diabetes but using lipid-lowering drugs (n ¼ 1243), there was a significant decrease in serum TAG across the serum 25(OH)D quartiles whereas no significant trend was observed for serum TC (Table 4) .
When serum 25(OH)D was used as a continuous variable in a multiple regression model with gender, age, BMI and month of blood sampling, the associations with HDL-C and TAG were found in both sexes and in all age and BMI groups tested in nondiabetic nonsmokers not taking lipid-lowering medication (Table 5) .
For serum 25(OH)D, the expected seasonal variation was observed with 26.3% higher concentrations during the summer as compared with the winter. The serum HDL-C values were higher and the serum TAG concentrations were lower during the summer than during the winter, but the differences did not reach statistical significance (Table 6 ). Vitamin D and serum lipids R Jorde et al Vitamin D and serum lipids R Jorde et al
Longitudinal study
Discussion
In this study there were highly significant positive associations between serum 25(OH)D and serum TC, HDL-C and LDL-C, and significant negative associations between serum 25(OH)D and both LDL-C/HDL-C ratio and TAG in the nonsmokers after adjustment for gender, age, BMI and month of blood sampling. In particular, the cross-sectional associations between serum 25(OH)D and serum HDL-C and TAG were strong and significant in both genders and in all age and BMI subgroups tested. In addition, an increase in serum 25(OH)D over time was associated with a decrease in serum TAG, which to the best of our knowledge has not been reported before.
The positive association between serum 25(OH)D and HDL-C has previously been reported from our group in a study on 438 overweight and obese subjects (Jorde et al., 2009 ). The association between serum 25(H)D and lipids is also reported from other studies, but the results are not consistent. Thus, in a study on 6810 45-year-old subjects by Hyppönen et al. (2008) , and in a study on 3069 older men by Lee et al. (2009) , a negative association between serum 25(OH)D and TAG was found, but the association between serum 25(OH)D and HDL-C was not significant after adjustment for confounders. However, in both the studies subjects with high serum 25(OH)D concentrations tended to have higher HDL-C concentrations than those with lower serum 25(OH)D concentrations. Conversely, in a study on 201 men and 180 women, Gannagé-Yared et al. (2009) found no significant association between serum 25(OH)D and TAG, whereas in men there was a significant negative relation with serum LDL-C. A negative relation between serum 25(OH)D and both TC and LDL-C was also reported by Chiu et al. (2004) in a study on 126 subjects, whereas in that study no association between serum 25(OH)D and TAG was found. And finally, no significant association between fasting serum lipids and serum 25(OH)D was found in 524 subjects in the MRC-Ely study (Forouhi et al., 2008) .
In the larger studies, however, that is, those by Hyppönen et al. (2008) , Lee et al. (2009) and our own, it appears that the relation between serum 25(OH)D and TAG is consistent. However, our finding of a positive relation between serum 25(OH)D and serum TC, HDL-C and LDL-C needs further confirmation. Our observation supports the suggestion that a high serum 25(OH)D concentration is associated with a desirable lipid profile with low serum TAG concentration and a low LDL-C/HDL-C ratio (Miller et al., 1977; Bansal et al., 2007; Fernandez and Densie Webb, 2008) . If confirmed this could contribute to an explanation of the association between low serum 25(OH)D concentrations and increased risk of mortality (Dobnig et al., 2008; Melamed et al., 2008; Pilz et al., 2009) . 
Vitamin D and serum lipids
Associations found in cross-sectional studies are no proof of a causal relationship. However, if such a causal relation exists, one would expect that changes in the serum 25(OH)D concentrations would be reflected in changes in serum lipid concentrations. In our study that was observed for TAG only, where an increase in the serum 25(OH)D concentrations from 1994 to 2008 was accompanied by a reduction in the serum TAG concentrations. Similarly, a nonsignificant reduction in serum TAG concentrations was observed during the summer months when the serum 25(OH)D concentrations are the highest. But again, this is no proof of causality, which has to come from intervention studies. So far only a few such intervention studies have been reported. Regarding serum TAG concentrations, which appear to be strongly associated with serum 25(OH)D, we have in our study of overweight and obese subjects found no effect on serum TAG of 20 000-40 000 IU vitamin D per week given for 1 year (Jorde et al., 2009); Heikkinen et al. (1997) found no effect by supplementation with 300 IU vitamin D for 3 years in 323 postmenopausal women; Andersen et al. (2009) found no change in 173 Pakistani subjects living in Denmark and given vitamin D in daily doses of 400 or 800 IU for 1 year; whereas Zittermann et al. (2009) in their study on 200 overweight subjects found a significant 13% decrease in the serum TAG in those given 3320 IU daily for 1 year. These discrepancies could be due to the doses of vitamin D given as well as differences between the study groups. Accordingly, the effect of different doses of vitamin D on serum TAG remains to be determined.
If there is a relation between serum 25(OH)D and lipid concentrations, this could be explained by several mechanisms. For TAG, one factor could be a vitamin-D-induced increase in calcium absorption leading to reduced formation of calcium-fatty soaps in the gut and thereby increased absorption of fat (Reid, 2004) . At least in subjects with low serum 25(OH)D concentrations, supplementation with vitamin D leads to increased formation of 1,25(OH) 2 D, which again may increase lipogenesis and lipolysis (Zemel et al., 2000) .
Owing to the unexpectedly high serum 25(OH)D concentrations in smokers than nonsmokers, for which we at present have no good explanation (Grimnes et al., 2010) , the analyses were performed again according to smoking status and yielded similar results in nonsmokers and smokers. However, in the subjects using lipid-lowering drugs, the increase in serum cholesterol with increasing serum 25(OH)D quartiles was not observed. One possible explanation could be that in subjects with higher serum 25(OH)D concentrations statins are more effective, as it has been suggested that vitamin D and statins have synergistic effects on serum cholesterol concentrations (Schwartz, 2009) . In the subjects with diabetes the relation between serum 25(OH)D and TAG was highly significant, whereas that was not observed regarding serum cholesterol, possibly because of the low number of subjects with diabetes studied.
Our study has some limitations. First of all we measured nonfasting lipid concentrations in both 1994 and 2008. Second, in the longitudinal study we had only two measurements of serum 25(OH)D and lipids, and ideally there should have been a larger series of measurements to evaluate the effects of changes over time. We did not measure apolipoprotein A-1, which has been reported to be associated with serum 25(OH)D (Auwerx et al., 1992; John et al., 2005) , and would therefore have been of particular interest in this study. We did not have a detailed food frequency questionnaire for evaluation of vitamin D intake, nor did we have a measure of habitual solar exposure. However, the strengths of our study are that we included a large group of subjects and adjusted for relevant confounders, and in the longitudinal study that the observation time was long and similar in all subjects. Also, the fact that we found the expected relation between serum 25(OH)D and BMI at baseline (Snijder et al., 2005) adds external validity to the findings.
In conclusion, high serum 25(OH)D concentrations are associated with a favorable lipid profile.
